Difference between revisions of "Team:BCU"

Line 50: Line 50:
 
//-->
 
//-->
 
</script>
 
</script>
 +
<!------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------->
 +
<!--- Content of the page  --->
 +
<!------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------->
 +
 +
 +
<div class="igem_2018_team_content">
 +
<div class="igem_2018_team_column_wrapper">
 +
<div class="clear extra_space"></div>
 +
 +
  <div class="left" style="width:10%;height:1px;float:left"></div>
 +
  <div class="main" style="width:80%;float:left">
 +
  <div style="width:100%;text-align:center"><h1>Braking Bad</h1><br><br></div>
 +
    <div style="width:100%;text-align:center">
 +
      <h3>Torwards a safer CAR-T therapy</h3>
 +
<img style="padding:0 10px 0 0;width:30%;float:left" src="https://static.igem.org/mediawiki/2018/e/ea/T--SYSU-CHINA--description001.jpg"></img>
 +
      <p style=text-align:justify;text-justify:inter-ideograph">
 +
CAR-T (chimeric antigen receptor T cell) therapy is one of the most promising treatment for cancer, with multiple ongoing clinical trials worldwide and 2 therapies approved by the FDA. However, the without proper control after administration of CAR-T cells, severe adverse effects associated with CAR-T therapy may bring fatal risks to the patients, especially during the clinical trial stages. While suicide switches serve as common methods for controlling adverse effects, they completely halt the expensive treatment.<br>
 +
 +
This year, team SYSU-CHINA aims to provide a safer yet affordable CAR-T therapy, by developing a reversible safe switch controlled by small molecules called CAR BRAKE. By expressing U24 protein of the human herpesvirus 6A under the control of tet-ON promoter, we can downregulate CAR molecules on the cell surface through endosomal recycling inhibition. This could potentially be used as a universal add-on for all CAR-Ts and TCR-Ts to ensure safety.<br> 
 +
 +
In addition, we are also ambitious to provide a method for monitoring CAR-T activity, using synthetic NF-AT promoter and reporter genes.
 +
 +
      </p>
 +
 +
  </div>
 +
  </div>
 +
  <div class="right" style="width:10%;height:1px;float:left"></div>
 +
 +
</p>
 +
<!--
 +
NewPP limit report
 +
CPU time usage: 0.005 seconds
 +
Real time usage: 0.005 seconds
 +
Preprocessor visited node count: 9/1000000
 +
Preprocessor generated node count: 42/1000000
 +
Post‐expand include size: 41/2097152 bytes
 +
Template argument size: 0/2097152 bytes
 +
Highest expansion depth: 2/40
 +
Expensive parser function count: 0/100
 +
-->
 +
 +
<!-- Saved in parser cache with key 2018_igem_org:pcache:idhash:1205-0!*!*!*!*!*!* and timestamp 20180713073608 and revision id 41931
 +
-->
 +
</div>             <div class="visualClear"></div>
 +
            </div>
 +
    </div>
 +
 +
        </div>
 +
    </div>
 +
</html>
 +
 
</body>
 
</body>
 
</html>
 
</html>

Revision as of 07:37, 13 July 2018

无标题文档

Braking Bad



Torwards a safer CAR-T therapy

CAR-T (chimeric antigen receptor T cell) therapy is one of the most promising treatment for cancer, with multiple ongoing clinical trials worldwide and 2 therapies approved by the FDA. However, the without proper control after administration of CAR-T cells, severe adverse effects associated with CAR-T therapy may bring fatal risks to the patients, especially during the clinical trial stages. While suicide switches serve as common methods for controlling adverse effects, they completely halt the expensive treatment.
This year, team SYSU-CHINA aims to provide a safer yet affordable CAR-T therapy, by developing a reversible safe switch controlled by small molecules called CAR BRAKE. By expressing U24 protein of the human herpesvirus 6A under the control of tet-ON promoter, we can downregulate CAR molecules on the cell surface through endosomal recycling inhibition. This could potentially be used as a universal add-on for all CAR-Ts and TCR-Ts to ensure safety.
In addition, we are also ambitious to provide a method for monitoring CAR-T activity, using synthetic NF-AT promoter and reporter genes.

</body> </html>